BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Creative Do-It-Yourself Ventures for Each Expertise Level - 2Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- 3Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- 4Russia Creates New Military Branch Dedicated To Drone Warfare
- 5FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 10 High priority Contraptions for Tech Aficionados
- New law puts familiar drinks, creams and gummies in legal limbo
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- Desired Travel Objections Worldwide: Where to Go Straightaway
- Oil rises above $115 and Asia stocks slide as Iran war escalates
- Africa's energy giants eye long-term gains on Iran war disruption
- Artemis II crew cleared to depart Earth orbit, head for moon
- What's the Fate of 5G Innovation?
- Here's what can happen if you drive under the influence of pot
